India is pushing GSK and Merck to slash the cost of HPV vaccines

The Indian government is negotiating with GlaxoSmithKline ($GSK) and Merck ($MRK) to secure a low-cost supply of human papillomavirus (HPV) vaccines, The New Indian Express writes. India is reportedly trying to get the manufacturers to sell Cervarix and Gardasil at $4.50 a dose, the same price the GAVI Alliance pays for the vaccines. Developed countries can pay more than $100 for the vaccines. Article

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.